By |

Q BIOMED VISION

Our vision is to create a pipeline of innovative biomedical assets in various stages of development in multiple therapeutic areas. Our strategy will minimize risk, share success and accelerate our technologies from incubation to monetization.

Development Pipeline

Strontium Chloride Sr-89 Injection, USP (Strontium-89) is a non-opioid radioactive pharmaceutical injection to relieve bone pain in patients with painful skeletal metastases. In the body, strontium exerts its effect through its selective accumulation in and around skeletal metastases.

As a calcium analog, strontium is taken up by active bone tissue present around metastatic tumor cells, especially around osteoblastic tissue. Strontium then irradiates tumors cells from the adjacent bone tissue. The ratio between the dose deposited on a metastasis and normal bone is 8-40. Unabsorbed isotope is excreted in the urine in the first few days following injection. Multiple studies have confirmed that Strontium-89 has a palliative effect on pain caused by bone metastases.

In a multi-center Canadian placebo-controlled trial of 126 patients, pain relief occurred in more patients treated with a single injection of Strontium-89 than in patients treated with an injection of placebo. In a study of 500 patients with skeletal metastases from prostate and breast cancer, an overall response rate of 80% was seen after 3 months, with 10 to 20% of patients reporting complete freedom from pain.

Another study found a 33% complete response rate (“dramatic improvement”) to Strontium-89, compared with no response after placebo.

Strontium Chloride Sr-89 Injection, USP can be used in combination with analgesics and used concomitantly or sequentially with external beam radiotherapy and bisphosphonates.

Strontium-89 injection is a pure beta emitter, and selectively irradiates sites of primary and metastatic bone involvement with minimal irradiation of soft tissues distant from bone lesions. The presence of bone metastases should be confirmed prior to therapy.

For more information please visit www.strontium89.com

What is a pediatric non-verbal disorder?

The signs and symptoms of a pediatric non-verbal learning disorder do not match those of any well-described condition and currently there is no formally accepted diagnosis. This is because there are difficulties in characterizing this condition that still challenge the medical community. Pediatric non-verbal disorder is accompanied with developmental delay, most notably where the toddlers never speak or will start speaking and then regress. The diagnosis is based on the identification of deficits in social perception, social judgment and social interaction skills, based on a toddler’s recognition of significant perception problems, faulty understanding of facial expressions, tone of voice and speaker’s intention. Low scores in specific motor performance tests involving both hands suggest bilateral brain involvement and confirm the presence of motor coordination impairments, with worse performance in the right hemisphere compared to the left. Children with non-verbal disorder are described as clumsy and uncoordinated. Visuospatial deficits are the major characteristic of children with non-verbal disorder, even in the absence of severe motor problems. Differences between verbal and performance (non-verbal) IQ scores are not a requisite for the diagnosis of non-verbal learning disorder; still this finding has been particularly emphasized in affected children.

What causes non-verbal disorder?

Causes of non-verbal learning disorder have been linked to several complications that range from a specific mutated gene as with Fragile X Syndrome and Dravet Syndrome or autoimmunity, where the body’s immune system is attacking parts of the brain. Trauma, microbial infections and enviromental factors have also been linked to non-verbal learning disorder. Ongoing research is helping to further explain the root cause of why children become non-verbal or minimally verbal.

For more information please visit www.QBioMed.com

Additional Information

Q BioMed Inc

Profile

Q BioMed, Inc. is a biomedical acceleration and development company. We are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support and expansion capital they need to meet their developmental potential so that they can provide products to patients in need.

Contact Information

Website: www.qbiomed.com
Email: info@qbiomed.com
Main Phone: +1 888 357 2435
Address: 366 Madison Avenue
Address 2: 3rd Floor
State: NY
City / Town: New York
Country: USA
Postal Code: 10017

Issuer Information

Exchange: OTCQB
CEO: Denis D Corin
Employees: 2
Issuer Type: CS - Common Stock
Sector/Industry: Cyclical
NAICS: Pharmaceutical Preparation Manufacturing(325412)


Gathering Data... Please wait
Q BioMed Inc

Profile

Q BioMed, Inc. is a biomedical acceleration and development company. We are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support and expansion capital they need to meet their developmental potential so that they can provide products to patients in need.

Contact Information

Website: www.qbiomed.com
Email: info@qbiomed.com
Main Phone: +1 888 357 2435
Address: 366 Madison Avenue
Address 2: 3rd Floor
State: NY
City / Town: New York
Country: USA
Postal Code: 10017

Issuer Information

Exchange: OTCQB
CEO: Denis D Corin
Employees: 2
Issuer Type: CS - Common Stock
Sector/Industry: Cyclical
NAICS: Pharmaceutical Preparation Manufacturing(325412)
$ 2.04 $ 0.02 (0.99%)
Last Price 2.04 Change $ 0.02 Change % 0.99 Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open 2.15 High 2.15 Low 1.95 Prev Close 2.02
Last Trade Volume 38,566 52 Wk Hi 3.95 52 Wk Low 0.90
Market Cap 29.1 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 14,240,361.00 EPS (TTM) -0.88 PE Ratio N/A Exchange OTCQB
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 8 8 8 8
Low Target Price Estimate 8 8 8 8
Mean Target Price Estimate 8 8 8 8
Standard Deviation 0 0 0 0
Date of Most Recent Estimate 07/07/17 07/07/17 07/07/17 07/07/17
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 1 1 1 0
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1 1 1 0